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Abstract: Extracellular vesicles (EVs) are nano-sized membrane vesicles involved in intercellular communication. 
EVs have pleiotropic actions in physiological and pathological conditions. The ability of EVs to transports 
proteins, drugs and nucleic acid, to target specific cells and to increase the stability of therapeutic cargo, make EVs 
interesting as new devices for the treatment of human disease. In a recently published issue of European journal of 
pharmaceutical sciences, Silva and colleagues reviewed the ability of EVs to modulate tissue repair and regeneration, 
focusing on their roles and therapeutic potential as immunomodulatory messengers. In this perspective, we 
discussed the open questions regarding the dual role of EVs in immune system, as well as the technical limitation of 
the procedure for EVs isolation and administration in clinical practices. EV-based therapies require further studies 
to consider EVs as promising candidate for a novel cell-free therapy in the context of regeneration medicine.
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In the past decade, the scientiﬁc interest in the role played 
by extracellular vesicles (EVs) in human physiology and in 
pathogenesis of major human diseases has rapidly increased. 
Huang-Doran and colleagues considered EVs an “umbrella 
term” that includes exosomes and different microvesicles, 
distinguished by their size and biogenesis (1).
EVs are commonly heterogeneous in size, ranging from 
20 to 1,000 nm in diameter depending on their origin and 
mechanism of release, direct shedding or budding from the 
plasma membrane. Exosomes are vesicles with a diameter 
of 20–100 nm formed by the inward budding of endosomal 
membranes to form large multivesicular bodies and released 
extracellularly when MVBs fuse with the plasma membrane. 
Larger microvesicles with diameter of 100 nm–1 mm result 
from the direct outward budding and ﬁssion of the plasma 
membrane (2).
In the 1980s, exosomes were thought to act as ‘garbage 
bags’ with the main function to discard the cellular 
waste, now they are considered as important intercellular 
communication devices (3). 
Evs have been detected in several biological fluids such 
as blood, saliva, urine, bronchoalveolar lavage fluid, synovial 
fluid, breast milk, amniotic fluid and malignant ascites (4). 
EVs carry a plethora of molecules including proteins, 
lipids, small and long, coding and non-coding RNAs 
that interact with local and distant cellular targets, thus 
modifying cell phenotypes. EVs add an alternative to the 
paracrine and endocrine cellular communication (5). EVs 
can interact with recipient cells with different endocytic 
mechanisms including clathrin-mediated endocytosis, 
clathrin-independent endocytosis, phagocytosis and 
macropinocytosis. The selected pathway depends on the 
expression of surface proteins on the recipient cells and 
on proteins present in EVs (6). After internalization by 
target cells, the mechanism by which EV cargos escape the 
degradative pathway of the recipient cells is still unclear (7). 
EVs have a key role in several biological processes, they 
are considered as a new paradigm in cell signaling. EVs 
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carry molecules that can activate downstream canonical 
pathways in the target cells (8). 
The widespread research in the ﬁeld of the vesicle role 
in cancer highlights the effects of EVs in modulation of the 
microenvironment. Increasing evidence shows that tumor-
derived exosomes have multiple roles in tumorigenesis; they 
can contribute to cancer growth inducing anti-apoptotic 
and oncogenic pathways such as invasion, metastasis and 
angiogenesis. Exosomes can promote tumor immune 
evasion with T-cell apoptosis induction (9-11). 
Recently, exosomes attracted the interest of the scientiﬁc 
community for their potential use in therapy as a targeted 
and non-immunogenic delivery system for drugs or 
biological molecules (12).
EVs are involved in the maintenance of  t issue 
homeostasis and they contribute to tissue repair and 
regeneration (13) as extensively showed in the review of 
Silva and colleagues (14). 
Because Evs are involved in pathological processes and 
their presence in biological fluids allows their use for easy 
liquid biopsies (10), EVs have also attracted great interest 
for the potential use as disease biomarkers (15).
The authors of the review “Extracellular vesicles: 
Immunomodulatory messengers in the context of tissue 
repair/regeneration” preferred to indicate the nanovesicles 
discussed in the paper as EVs, in order to review studies 
that investigate a broad range of different population of 
vesicles (exosomes, microvesicles, ectosomes) according to 
the nomenclature guidelines proposed by ISEV.
In this review, the authors discussed the role of EVs in 
tissue repair and regeneration and the potential therapeutic 
effects of natural, modified and artificial EVs in control 
of inflammation and regenerative medicine. The authors 
described effects of EVs in tissue repair as mediators of 
cell proliferation and differentiation and they reported 
the effects of EVs in the extracellular matrix remodeling. 
Moreover, they focused the attention on the role of EVs 
in therapy as vehicles of new drugs and as a novel drug-
delivery system. 
After isolation, EVs could be utilized in regenerative 
medicine through several methods, in combination 
with cells and/or other therapeutics or separately. It was 
described that EVs can be directly injected into tissue 
or circulation. EVs can be introduced in regenerative 
therapies, mixed with hydrogels, or it is possible to coat 
scaffolds using ﬁbrin gels. 
Since EVs are complex devices with a pleiotropic 
role, it is necessary to understand their advantages and 
disadvantages before to candidate them as therapeutic 
agents, considering the limitations that have emerged in the 
clinical trials for their use.
In this perspective, we analyzed the dual role of 
EVs in immune system, the technical limitations of a 
non-standardized procedure for the purification and 
quantiﬁcation, necessary to utilize the vesicles in therapy. 
The authors in this review focus on the use of EVs, as 
a promising candidate for a “novel cell-free” therapy, in 
the resolution of inflammation during the repair of tissue 
damage. Resolution of inflammation is one-step of tissue 
repair and regeneration.
The role of EVs in regenerative medicine is supported 
by several experimental data. It was demonstrated that 
exosomes released by mesenchymal stem cells (MSCs) 
have been tested in preclinical settings for the treatment of 
cardiovascular diseases (15), kidney injury (16), osteochondral 
regeneration (17), skeletal muscle regeneration (18) and 
neurological disease (19). EVs can modulate the immune-
activity (20), through the regulation of cytokine expression. 
EVs can also affect the inﬁltration of immune cells into the 
damaged tissue, inhibiting the pro-inflammatory processes 
and immune cells activity. 
It has been also demonstrated the role of EVs in 
immune suppression and/or immune stimulation. Several 
papers reported preliminary application of EVs as 
immunotherapeutic agents for the treatment of inflammation 
triggered by the injury. Blazquez et al. demonstrated the 
immunomodulatory and anti-inflammatory effects of human 
adipose MSCs derived exosomes (exo-hASCs) in in vitro 
stimulated T cells. hASCs exosomes inhibit the activation 
and differentiation of cytotoxic and helper T cells, as well 
as reduced T cell proliferation and IFN-γ release on in vitro 
stimulated cells (21).
Zhang et al. also demonstrated an immunosuppressive 
role for exosomes isolated from embryonic stem cells 
(ESC). Exosomes were shown to induce high levels of anti-
inflammatory IL-10 and tumor growth factor-β1 (TGF-β1) 
in human monocytes, and they reduced the levels of pro-
inflammatory IL-1B, IL-6, tumor necrotic factor α (TNFα), 
and IL-12P40 (22).
Wen et al. demonstrated that exosomes released by 
human bone marrow mesenchymal stem cells (hBMSCs) 
suppress immune reaction during Langerhans islet 
transplantation, promoting islet function and inhibiting 
immune rejection (23). 
On the other side, data in the literature report the role 
of exosomes in immune system stimulation. Rahman et al. 
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demonstrated the role of Islet-derived MSCs exosomes as 
autoantigen carrier in the promotion of local autoimmune 
response. The cells of Langerhans islet of NOD mice 
(MSC-like cells) release immunostimulatory exosomes that 
could activate autoreactive B and T cells endogenously. The 
immunization with exosomes accelerated the effector T 
cell-mediated destruction of islets (24). 
The exosomal features and their potential role in 
immune regulation suggest a possible clinical use of EVs as 
adjuvant or therapeutic agents, but several problems limit 
the clinical use of EVs. 
Clinical Good Manufacturing Practice (cGMP)-grade 
standards for EV clinical use require standardized criteria 
for EV isolation and storage methods. It is necessary 
to standardize a long-term storage method, in order to 
preserve the EV functions and minimize the variability of 
EVs stability and composition. 
Nowadays, a reliable quality control assay to test EV 
membrane integrity after their preservation is lacking (25). 
This limit does not ensure the reproducibility of the effects 
obtained after the EV administration. 
Another problem to use the EVs as therapeutic agents 
or drug delivery vehicle is the lack of an optimal method 
for their isolation. The techniques most commonly 
applied for EV isolation, ultracentrifugation and polymeric 
precipitation, are not ideal due to several reasons: (I) the 
technique is cumbersome; (II) it does not avoid the co-
precipitation of culture medium components (serum or 
bovine albumin) with EV pellets; this could affect the 
EV biological effects; (III) recovery is low and the scale 
up process not easy to standardize. The culture medium 
components could induce modulation in target cells 
that can be confused with the effects assigned to EVs. 
Therefore, it is necessary the standardization of a unique 
EV isolation technique that could prevent the presence of 
other components in EV pellets. 
The clinical application of EVs also requires the 
standardization of the administered dose, but actually 
does not exist a unique technique of quantification, the 
achievement of comparable results is therefore difﬁcult to 
obtain. To date, the amount of EVs is calculated in two 
different ways: in several studies, EVs released by a deﬁned 
cell number are used, others scientists utilize the count of 
the EV number (11). 
Furthermore, the characterization of the active 
molecules contained in EVs is a fundamental step for EV 
approval in clinical practice by the National Agencies 
for Drug Regulation. It is also important to consider the 
oncogenic potential of EVs that could limit the clinical use 
of vesicles as therapeutic agent. EVs contain oncogenic 
proteins, mRNAs, miRNAs and transcription factor that 
can potentially alter the genome and the proteome of 
recipient cells, thus favoring angiogenesis, proliferation and 
metastasis (16-20). 
In the review, the authors discussed about the effects 
of EVs in regenerative medicine, but it is important to 
consider the dual effect of EVs on the immune system. 
There are beneﬁts and disadvantages about the use of EVs 
as therapeutic immune-modulators in the context of tissue 
repair/regeneration. 
Although, MSC derived EVs have immune-modulating 
activity (20), the effects of long-term EV administration are 
unknown. Since EVs display MHC (26) and carry several 
allogeneic proteins, they could stimulate an auto immune 
response in the patient in which they are injected. 
Few data support the use of allogenic and xenogeneic EVs 
as therapeutic application to enhance the amount of EVs 
injectable in therapy. It was demonstrated that allogenic EVs 
are tolerated in immune–competent animals (5,7). 
Nowadays, one clinical trial reported the use of allogenic 
EVs in human therapy. EVs released by MSCs have been 
first administered for compassionate use in a patient with 
steroid refractory graft versus host disease (27). Multiple 
injections (every 2–3 days) of EVs released by MSCs of 
unrelated bone marrow donors showed anti-inflammatory 
effects and ameliorated the clinical symptoms of the 
patient without adverse effects, indicating the safeness 
of EV administration. The first trial on MSC-derived 
microvesicles and exosomes on β-cell mass in type I diabetes 
mellitus is now enrolling (NCT02128331). 
Arslan et al. also demonstrated that xenogeneic EVs 
might be tolerated in mice, in vivo (28), but nowadays there 
are not data about the potential time-dependent effect 
on the immune system modulation, following repeated 
injection of EVs in human. 
In order to use EVs for therapeutic applications might 
be optimal to derive therapeutic EVs from an autologous 
source, to reduce the side effects and cost of EVs therapies.
Escudier et al., demonstrated the role of exosomes 
isolated from conditioned medium of autologous 
dendritic cell (DC) of patients with advanced metastatic 
melanoma, incubated with melanoma peptide antigens to 
induce presentation of the antigen on the cell surface, in 
association with MHC. EVs reintroduced into patients 
promoted an immune response against melanoma. Some 
patients reported minor inflammatory responses at the 
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site of exosome injection (mild swelling, redness, and 
DTH responses) and low-grade fever were observed 
after exosome administration. The patients tolerated 
administration of exosomes for up to 21 months (29), but 
it is necessary to evaluate the exosome effects in a long-
term treatment. 
Jefferson et al., in the pilot immunotherapy trial for 
recurrent malignant gliomas, suggested the use of autolog 
exosomes isolated from tumor cells removed during 
surgical craniotomy. The isolated cells, treated with an 
investigational new drug (an antisense molecule), that target 
surface receptor protein, are re-implanted (encapsulated in a 
small diffusion chamber) in the abdomen of patient, within 
24 hours after the surgery. The lack of the surface receptor 
led tumor cells, treated with the antisense molecules, to 
apoptosis. The authors supposed that released exosomes 
are full of tumor antigens that together with the antisense 
molecules could stimulate the immune system against tumor 
recurrence. The patient recruitment of this trial is currently 
ongoing. (NCT02507583) (www.clinicaltrial.gov).
One of the most important advantage in the use of a 
cell-free therapy is the possibility to inject EVs locally 
thus minimizing the side effects of cells administration. 
Moreover, EVs can be engineered and addressed to speciﬁc 
organs. The use of EVs in therapy is more attractive than 
the injection of the cells, in fact, injected cells may die or 
not fully home into the site of damaged tissue whereas EVs 
can be locally administered with a controlled dosage (30). 
The authors in the review also discuss about the use of EVs 
as drug delivery vehicles in tissue repair and regeneration, 
taking advantage of their natural biocompatibility and cell 
targeting. 
Recent studies suggest the production of engineering 
artificial lipid vesicles that incorporate EV components 
such as specific lipids or proteins in order to increase 
stability, targeting, and uptake. Engineered EVs with high 
levels of phosphatidylserine result in vesicles with a rigid 
membrane, resistant to lipolytic and proteolytic degradation 
in the circulation (31). The engineered structure of the 
EV membrane could enhance the stability of the vesicles 
in vivo and increase the probability to target the specific 
organ before to be cleared or degraded. The authors 
indicate that EVs may be regarded as a promising candidate 
for a novel cell-free therapy for tissue repair damage. 
Unfortunately, the data present in the literature does not 
suggest clear advantages of the EVs for the therapeutic 
applications. Several problems could be related to the use 
of EVs as immunomodulatory messengers in the context 
of tissue repair/regeneration. In the next future, the goal 
of the researchers should be to standardize the technique 
to manipulate the EVs for their use in therapy and 
demonstrate the long-term EVs effectiveness and safety for 
the treatment of human tissue damage.
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